Axis-Shield, the international in vitro diagnostics company, today announces the launch of a test for D-dimer to run on the widely-placed AxSYM automated immunoassay system marketed by Abbott Laboratories. D-dimer is an important blood coagulation marker which is raised in deep vein thrombosis (DVT) and pulmonary embolism (PE). These are serious and relatively common clotting conditions that contribute to patient morbidity and mortality, with substantial costs to healthcare systems in the developed world, where the incidence is around 1:1000. The AxSYM D-dimer test has a negative predictive value greater than 98%, giving it high utility in ruling out DVT and PE.
Axis-Shield
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
CoreLink’s 3D Anterior Lumbar Approved by FDA
The implant allows for better imaging by minimizing material density.
Endo Resumes Lawsuit Against FDA Over Bulk Drug Compounding Decree
The company claimed the agency’s handling of bulk compounding laws violates the 2013 Drug Quality and Security Act, treating the laws as non-binding guidance rather than a legal mandate.
FDAnews Device Daily Bulletin
AXIS-SHIELD ANNOUNCES LAUNCH OF FIRST ASSAY UNDER AXSYM XTRA PROGRAMME
June 1, 2006